|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 17, 2019 ) Major players in the pyrogen testing market include Associates of Cape Cod, Inc. (U.S.) Charles River Laboratories International, Inc. (U.S.), Ellab A/S (Denmark), GenScript (U.S.), Hyglos GmbH (Germany), Lonza Group (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (U.S.), Wako Chemicals USA Inc. (U.S.), and Wuxi PharmaTech (CAYMAN) Inc. (China).
There is a high degree of consolidation in the pyrogen testing market, with few large players dominating the market. High degree of consolidation is major barriers for new entrants in this market. Small and medium-sized players account for a small share of the market and their business interests remain concentrated in local markets across emerging geographies. Charles River Laboratories International, Inc. (U.S.), Lonza Group (Switzerland), Merck KGaA (Germany), and Associates of Cape Cod, Inc. (U.S.) are the leaders in this market. The combined market share of these four companies, far exceed that of all other players. Furthermore, acquisitions by market leaders in this field have strengthened their market positions and have served to further consolidate the market.
Download Free PDF - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=255266155
Agreements, Collaborations, and Partnerships and expansions were the two most important growth strategies employed in this market. An analysis of market developments between 2011 and 2016 revealed that expansion was the most adopted growth strategy employed by the market leaders in this period. For instance, in January 2016, WuXi PharmaTech announced its plans to establish a new state-of-the-art integrated biologics solution center in Shanghai, China. The company plans to invest USD 120 million in this dedicated, 250,000-square-foot facility, which will be functioning in 2017 and accommodate 800 scientists. The facility will offer integrated solutions for biologics discovery, development, and clinical manufacturing. This facility expanded the company’s global manufacturing footprint. This strategy was adopted by Charles River Laboratories International (U.S.), GenScript (U.S.), Lonza Group (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (U.S.), and Wuxi PharmaTech (CAYMAN) Inc. (China)
The other important growth strategies were Agreements, Collaborations, and Partnerships, implemented to gain immediate technological competency and widen geographic presence. For instance, in July 2013, Hyglos GmbH entered into a sales partnership with Bioclass S.r.l. (Italy). Bioclass S.r.l. will represent Hyglos and sell the companys Hyglos endotoxin detection assays and endotoxin removal systems in Italy. This strategy was adopted by Associates of Cape Cod, Inc. (U.S.), Merck KGaA (Germany), Charles River Laboratories, Inc. (U.S.), Hyglos GmbH (Germany), Lonza Group (Switzerland), Thermo Fisher Scientific (U.S.), and WuXi PharmaTech (Cayman) Inc. (China)
View Complete Press Release - https://www.marketsandmarkets.com/PressReleases/pyrogen-testing.asp
MarketsandMarkets™
Mr. Shelly Singh
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
